To help identify effective interventions to limit the cardiovascular side effects of antipsychotics, a three-part hypothesis is described: (1) risk factors for heart disease correlated with antipsychotic drug treatment require an intervention that targets the antipsychoticrelated mechanism of risk; (2) antipsychotic drugs cause weight gain and dyslipidemia at least in part via upregulation of the SREBP transcription factor in the liver and the genes under its control; and (3) Chinese herbal remedies that downregulate SREBP can limit weight gain and dyslipidemia caused by antipsychotics and prevent progression of coronary artery disease.
Antipsychotic drugs increase risk for type 2 diabetes and heart disease. Heart disease is the reason why most individuals with schizophrenia live short lives. Life expectancy is reduced by an average of 15 years and 50-75% of individuals with schizophrenia die from coronary heart disease. Drug-switching trials have confirmed a causal relationship between commonly prescribed antipsychotic drugs (olanzapine, quetiapine or risperidone) and weight gain and dyslipidemia. Both are important risk factors for type 2 diabetes and heart disease. Cognitive-behavioural and psycho-educational interventions to control weight gain in those treated with antipsychotics have shown a modest short-term effect equivalent to a mean 3% change in body weight-not enough to significantly improve cardiovascular health-and not sustained at 1-year follow-up. 1 Cardiovascular risk factors that are changed by exposure to antipsychotics may therefore require interventions that target treatment-related mechanisms of risk if we are to change key physical health outcomes of treated psychosis.
One important mechanism of risk may be the effect of antipsychotic drugs on gene expression. In cell lines derived from human brain tissue, antipsychotic drugs preferentially upregulate genes that control the biosynthesis of cholesterol and fatty acids. 2 This is due to increased proteolytic cleavage of the sterol regulatory element binding protein (SREBP1 and SREBP2) transcription factor. In the brain, these expression changes may have an important role in cell membrane permeability and cell signalling; in peripheral tissue they may have an important role in cardiovascular health. In human liver cells, antipsychotic drugs upregulate key cholesterol transport genes predominantly under the control of liver X receptors, which are in a regulatory feedback loop with SREBP. 3 Upregulation of SREBP in the liver could lead to weight gain and dyslipidemia. There is evidence a similar effect is observed beyond the strict confines of experimental studies. Expression of lipid biosynthesis genes under the control of SREBP1 were significantly upregulated in the peripheral blood of patients treated with olanzapine monotherapy compared with un-medicated matched patient controls. 4 Traditional Chinese herbal remedies, especially in combination, have been proposed for the prevention and treatment of coronary artery disease 5 and several have been shown to downregulate SREBP. 6 These include berberine, danshen, morroniside, fufang zhenzhu tiaozhi fang and fenugreek. 6 Berberine, a plant alkaloid with a long history of medicinal use in both Ayurvedic and Chinese medicine, may be of particular interest. It is found in the roots, rhizomes, stems and bark of plants including Berberis vulgaris (Barberry), Coptis chinensis (Chinese Goldthread) and Hydrastis canadensis (Goldenseal). Alone or as part of a multi-component herbal remedy, Berberine has been used to treat many ailments, including heart disease. 7 Berberine is also a potent hypoglycaemic agent, as good as metformin for the regulation of glucose metabolism in those with newly diagnosed type 2 diabetes and better than Metformin for lowering total cholesterol and triglyceride levels. 8 This is relevant because metformin has been proposed as a treatment for the metabolic side effects of antipsychotics. 9 Three months of treatment with berberine, however, was more effective than metformin for reducing waist circumference, waist-to-hip ratio, total and low-density lipoprotein cholesterol and triglyceride level, and for increasing high-density lipoprotein cholesterol, in women with polycystic ovary syndrome. 10 The INTERHEART study has shown that lipid ratios are the strongest risk factor for first heart attack and that abdominal obesity is a more important risk factor than body weight or body mass index. The greater improvement in waist circumference and lipids after treatment with berberine than metformin may therefore be clinically relevant for those with treated psychosis. Moreover, berberine in combination with policosanol, red yeast extract containing monacolin, folic acid and astaxanthin was more effective than berberine alone in correcting dyslipidemia (Cicero et al. (2007) in the study by Zeng et al.
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). Traditional Chinese medicine emphasises the value of combining herbal remedies to Letters to the Editor more effectively target multiple aspects of cardiovascular health and to decrease the likelihood of adverse side effects. A combination of traditional Chinese herbal remedies may therefore provide a more effective mechanism-based intervention for antipsychotic drug-induced weight gain and dyslipidemia than any single herbal remedy or any of the current alternatives. If this hypothesis is true then traditional Chinese herbal remedies may help increase the tolerability of current antipsychotic drugs and improve the physical health of the seriously mentally ill.
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